Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Other financing activities (2018 - 2025)

Voyager Therapeutics' Other financing activities history spans 8 years, with the latest figure at $434000.0 for Q2 2025.

  • For Q2 2025, Other financing activities fell 32.08% year-over-year to $434000.0; the TTM value through Jun 2025 reached $1.8 million, down 7.49%, while the annual FY2025 figure was $549000.0, 53.16% down from the prior year.
  • Other financing activities for Q2 2025 was $434000.0 at Voyager Therapeutics, down from $639000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $639000.0 in Q2 2024 and bottomed at $313000.0 in Q2 2022.
  • The 5-year median for Other financing activities is $434000.0 (2025), against an average of $476800.0.
  • The largest annual shift saw Other financing activities plummeted 46.03% in 2022 before it soared 52.87% in 2024.
  • A 5-year view of Other financing activities shows it stood at $580000.0 in 2021, then tumbled by 46.03% to $313000.0 in 2022, then surged by 33.55% to $418000.0 in 2023, then surged by 52.87% to $639000.0 in 2024, then crashed by 32.08% to $434000.0 in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Other financing activities are $434000.0 (Q2 2025), $639000.0 (Q2 2024), and $418000.0 (Q2 2023).